Share ownership Incyte Corporation

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 22/07/2026 am IST			After hours 05:30:00 am
117.39 ^USD	+1.50%		110.50	-5.87%

20/07	Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug	MT
20/07	Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating	MT

Share class: Incyte Corporation

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	19,97,82,155	19,60,78,472 ( 98.15 %)	0	98.15 %

Major shareholders: Incyte Corporation

Name	Stocks	%	Valuation
Baker Bros. Advisors LP 15.54 %	3,10,40,841	15.54 %	3 519 M $
Baker Bros. Advisors LP 15.39 %	3,07,44,412	15.39 %	3 485 M $
BlackRock Advisors LLC 7.293 %	1,45,70,131	7.293 %	1 652 M $
Dodge & Cox 6.133 %	1,22,52,356	6.133 %	1 389 M $
Vanguard Capital Management LLC 5.471 %	1,09,30,066	5.471 %	1 239 M $
STATE STREET CORPORATION 4.826 %	96,41,384	4.826 %	1 093 M $
Vanguard Portfolio Management LLC 3.884 %	77,59,183	3.884 %	880 M $
AQR Capital Management LLC 2.907 %	58,07,930	2.907 %	658 M $
Geode Capital Management LLC 2.354 %	47,03,184	2.354 %	533 M $
BlackRock Life Ltd. 2.007 %	40,10,584	2.007 %	455 M $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	107.58%
Others	7.68%
State Street Corp.	4.83%
Individuals	0.86%
SEI Investments Co.	0.38%
Schweizerische Nationalbank	0.25%
Sumitomo Mitsui Trust Group, Inc.	0.21%
Swedbank AB	0.19%
Governments	0.14%
Manulife Financial Corp.	0.06%
Danske Bank A/S	0.04%
Northwest Bancshares, Inc. (Pennsylvania)	0.03%
Banco Bilbao Vizcaya Argentaria SA	0.02%
The Bank of Nova Scotia	0.01%
Fifth Third Bancorp	0.01%
Hennessy Advisors, Inc.	0.01%
The Allstate Corp.	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	99.82%
United Kingdom	7.39%
Australia	2.99%
Canada	2.86%
Netherlands	1.46%
France	1.16%
Sweden	1.07%
Switzerland	1.01%
Norway	0.98%
Individuals	0.86%
Japan	0.61%
Denmark	0.34%
Luxembourg	0.33%
Ireland	0.3%
Germany	0.26%
Italy	0.19%
South Korea	0.15%
Belgium	0.1%
Spain	0.08%
New Zealand	0.06%
Puerto Rico	0.06%
South Africa	0.04%
Hong Kong	0.04%
China	0.04%
Finland	0.03%
Czech Republic	0.02%
Austria	0.02%
Brazil	0.01%
Liechtenstein	0.01%
Mexico	0.01%
Taiwan	0.01%

Based on 1000 largest holdings

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).

Employees

2,844

Sector

Pharmaceuticals

Calendar

28/07 - Earnings release - Q2 2026

More about the company